Indeed, SMARCA4-deficient NSCLC cells are also highly sensitive to the CDK4/6 inhibitor palbociclib in both cell viability (Fig. 1c) and long-term colony formation assays (Fig. 1d and Supplementary Fig. 2a), contrasting to SMARCA4-proficient/KRAS wild-type (WT) cells. Here, KRAS is linked to non-small cell lung carcinoma.